Arthur Bobin

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Xavier Leleu, Cyrille Hulin, Jérôme Lambert et al. · Nature Medicine · 2024 · 107 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Response to pneumococcal vaccination in multiple myeloma

Loïc Renaud, Susanna Schraen, Guillemette Fouquet et al. · Cancer Medicine · 2019 · 24 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study

Alexis Talbot, Arthur Bobin, Léa Tabone et al. · Haematologica · 2023 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Aurore Perrot, Cyrille Hulin, Ariane Boumendil et al. · Haematologica · 2024 · 17 citations · Full text

Pharmacy, Pharmacotherapy, Immuno-oncology Pharmacotherapy +1

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

Guillemette Fouquet, Stéphanie Guidez, Valentine Richez et al. · Oncotarget · 2018 · 16 citations · Full text

Medicine, Hematology, Pharmacotherapy +15